More dissenting voices add to pressure to repeal IPAB

2 May 2017

The Independent Payment Advisory Board (IPAB), a US government agency created as part of Barack Obama’s Affordable Care Act, has come under further criticism from pressure groups which are asking for it to be repealed.

This 15-member panel is tasked with achieving specified savings in Medicare without affecting coverage or quality but its critics include pharma companies and groups representing patients and physicians.

Pharmaceutical Research and Manufacturers of America (PhRMA), the trade group lobbying on behalf of pharma companies in the USA, is one of the critics and was one of the 650 healthcare organizations that signed a letter to Congress last week. US pharma giants Merck & Co (NYSE: MRK) and Pfizer (NYSE: PFE) are among the many signatories from the drug development industry.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK